The global active pharmaceutical ingredients market is projected to reach USD 248.3 billion by 2025 from USD 187.3 billion in 2020, at a CAGR of 5.8% during the forecast period according to analysis by ResearchAndMarkets

Fareva Excella, a state-of-the-art FDA approved site, dedicated to complex molecules, High Potent Active Pharmaceutical Ingredients (HPAPI) and to solid dosage forms, expands its high potent tablets and capsules operations with a major investment of 25 m€, ready to produce in 2023

Excella is using closed manufacturing systems with a capability of handling substances with an occupational exposure level (OEL) down to 0.01 microgram/cubic meter or even below. It allows to develop and manufacture high potent products (OEB 6), anti neoplastic products and sensitizing products including adequate packaging in blisters (Aluminium, PVC/Alu, PVC/PVCD, Polypropylene, Aquaba) and bottles (plastic, glass)..

Fareva is indeed completing a major investment program aiming to strengthen its capabilities to follow the strong demand in high potents drug products (oncology drugs represent more than 50% of the new chemical entities).

- In 2016, on the site of Fareva La vallee, France, high potent APIs capabilities have been added, including a pilot, a production building and R&D laboratories.

- In 2018-2019, Fareva Excella expanded is analytical capabilities and has added a high potent roller compactor.

- In 2021, Fareva Excella is adding a new 2,850 m2 building, able to manufacture 500 millions of tablets or capsules per year, with an empty suit for a future extension, up to OEB6 containment level. This operation will be committed in July 2023. Fareva Excella is FDA and PMDA approved.

To be noticed, the acquisition of the Novartis' Austrian site of Unterach specialized of injectable high potent drug products, completed in April 2021, is adding injectable high potent vials and PFS lines to reinforce the overall offer of Fareva in this field.

---